Patients face ongoing challenges with preauthorization despite reform promises

Sheldon Ekirch, a 31-year-old from Virginia, recently won a two-year battle with Anthem Blue Cross and Blue Shield for coverage of intravenous immunoglobulin (IVIG) infusions to treat her small-fiber neuropathy. An external review overturned Anthem’s previous denial, ensuring her family would no longer face financial strain after spending $90,000 out-of-pocket. Despite promises from health insurers to reform the prior authorization process, many patients continue to experience coverage denials, raising concerns about the industry’s commitment to patient welfare.

Want More Context? 🔎